XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net loss attributable to Myriad Genetics, Inc. stockholders $ (20.5) $ (39.5)  
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Depreciation and amortization 13.0 18.4  
Non-cash interest expense 0.2 0.5  
Non-cash lease expense 3.1 3.5  
Stock-based compensation expense 10.1 9.0  
Deferred income taxes (5.9) (11.8)  
Unrecognized tax benefits 0.2 0.3  
Impairment of goodwill and long-lived assets 10.7 0.0  
Changes in assets and liabilities:      
Prepaid expenses and other current assets (3.0) (2.5)  
Trade accounts receivable (10.5) (4.7)  
Inventory (0.2) 2.4  
Prepaid taxes (0.4) 90.3  
Other assets (0.3) (1.2)  
Accounts payable (3.2) 0.3  
Accrued liabilities (35.3) 8.4  
Deferred revenues (4.5) (1.6)  
Net cash provided by (used in) operating activities (46.5) 71.8  
CASH FLOWS FROM INVESTING ACTIVITIES:      
Capital expenditures (6.3) (7.1)  
Purchases of marketable investment securities (52.1) 0.0  
Proceeds from maturities and sales of marketable investment securities 17.1 15.3  
Net cash provided by (used in) investing activities (41.3) 8.2  
CASH FLOWS FROM FINANCING ACTIVITIES:      
Proceeds from common stock issued under stock-based compensation plans 0.3 26.5  
Payment of tax withheld for common stock issued under stock-based compensation plans (5.1) (0.5)  
Payment of contingent consideration recognized at acquisition 0.0 (3.3)  
Fees associated with refinancing of revolving credit facility 0.0 (1.2)  
Repayment of revolving credit facility 0.0 (70.0)  
Net cash used in financing activities (4.8) (48.5)  
Effect of foreign exchange rates on cash and cash equivalents (0.6) 0.4  
Net increase (decrease) in cash and cash equivalents (93.2) 31.9  
Cash and cash equivalents at beginning of the period 258.4 117.0 $ 117.0
Cash and cash equivalents at end of the period $ 165.2 $ 148.9 $ 258.4